Mark is the founder of PHMR and has developed the company into a successful health economics, pricing and market access consultancy working with a range of top 10 pharma companies. He has a vast amount of experience in the health economics, pricing, reimbursement and market access fields. He also possesses decades of experience with major international pharmaceutical companies and previous work in senior economics research positions.

Michael is involved across a range of health economics, outcomes research and market access projects at PHMR and is responsible for ensuring that the research delivered matches the strategic needs of our clients. Michael has extensive experience in the development of health economic models and indirect treatment comparisons, utility measurement and health valuation, strategies for collection and use of real-world data, as well as the development of dossiers to support HTA submission. He also has substantial experience in working with different stakeholders, including through the use of early scientific advice through HTA agencies, to lead the development of integrated evidence plans and allow for access needs to be incorporated from early in product development. Michael has led projects across many different therapeutic areas, with expertise in fields including oncology, GI, neuroscience, rare disease, and cardiovascular disease. Michael has also published his research in peer-reviewed journals and presented work at multiple international conferences. He has led educational initiatives to shape HTA policy which involved delivering symposiums at international conferences and developing publications to support the use of innovative methodologies to demonstrate the value of new immuno-oncology medicines.

Koonal is a health economist with expertise in stated preference methods, the measurement and valuation of health, and the use of social value judgements in HTA decision making. He has written extensively on patient-reported outcomes and HTA policy (focusing on the assessment of cancer and end of life treatments) and has published over 40 peer-reviewed journal articles and book chapters. He has led high-profile projects across a broad range of clinical and methodological areas, with his work on the generation and analysis of utility values used in a large number of HTA submissions. Koonal is a member of the EuroQol Group (an international network of researchers that developed the EQ-5D family of instruments) and currently serves on the Group’s Executive Committee. He is also an Honorary Research Fellow at the University of Sheffield’s School of Health and Related Research.

Matt is a health economist with extensive experience in conducting economic evaluations of new treatments and specialises in long-term modelling, with knowledge of a variety of software and conceptual models. He has contributed to and advised biopharma clients on submissions to a number of HTA agencies. He has also contributed health economic input to the design of numerous randomised controlled trials and analysed and synthesised trial data.

Vlad is a health economist with substantial experience of leading cost-effectiveness and budget impact modelling projects. He has extensive knowledge of statistical methods applicable to economic evaluation through his experience in trial-based economic evaluation and decision-analytic modelling to support HTA submissions. Vlad has expertise in long-term modelling in rare diseases, including therapeutic areas with sparse evidence of long-term costs and benefits of treatment. His other research interests include the application of propensity scores to adjust for confounding in observational studies and the use of indirect comparisons of efficacy of treatments in the absence of head-to-head trials.

Lynsey is the scientific office manager and administrator at PHMR. Her extensive experience in the life sciences and with rapidly growing healthcare consultancies results in a skill set which bridges the gap between business and science. She is passionate about bringing PHMR’s values to life by facilitating and supporting the development of lasting client partnerships; the delivery of quality science with integrity; and the cultivation of a supportive, skill sharing environment. Her drive to optimise organisation and efficiency reinforces the delivery of PHMR’s consistently high standards.

Gintare, Assoc CIPD, keeps HR operations aligned to the company values and brings the skills, knowledge and energy required to ensure PHMR is a great place to work.

Jasmine is experienced in developing and supporting HTA and market access strategy and has experience collaborating with national affiliates on behalf of our global clients. Jasmine provides project management and delivery for multiple aspects of HTA evidence generation, including systematic literature reviews, landscape analyses, HTA reviews, pricing research and engagements with key opinion leaders. Jasmine additionally contributes to PHMR’s operations and enjoys optimising organisation and communication for our projects to progress rapidly, efficiently and to the highest standards. Jasmine also has considerable experience in the analysis of HTA policy, including novel reimbursement frameworks for cell and gene therapies. Jasmine has over 10 years of experience in pharmacology, having previously worked in the UK and Europe for two world leading pharmaceutical companies. She has publications in several peer-reviewed journals and has presented her research at a range of international conferences.

Lefteris has a broad knowledge of health economics having served in multiple academic and commercial positions. He holds extensive experience with the collection, evaluation, and modelling of clinical and cost data having led the development of multiple global and regional economic models for HTA submission purposes, and having designed numerous clinical trial-based economic evaluations. He also carries great familiarity with HTA agency processes having been a part of the technical teams supporting expert committees of UK NICE clinical guidelines and represented pharmaceutical clients in agency committee discussions. His experience also expands in the generation of comprehensive economic value stories for pharmaceutical products used in discussions with payers.

Dave has considerable experience in the information and library field supporting health research. He is responsible for designing literature searches and strategies as well as managing the results of searches using reference management software to support the wide variety of projects and research that PHMR undertakes for clients. He has run literature searches to support numerous reviews including NICE single and multiple technology assessments, Cochrane reviews, Public Health Research Council projects, and British Thoracic Society clinical guidelines.

Adam is involved in a range of health economic and outcomes projects at PHMR. He brings a wealth of knowledge in conducting both quantitative and qualitative research in health valuation, utility measurement, patient and caregiver-reported outcomes, and psychometric testing. He has supported on projects across a range of indications such as oncology, musculoskeletal and rare disease, and psychological and mood disorders. Adam has contributed to the generation of evidence for outcomes dossiers and economic models, and advised on outcomes data collection for clinical trials. He has also published and presented research on patients’ treatment experiences at international conferences and in peer-reviewed journals.

Persefoni’s role at PHMR is to manage and deliver a wide range of projects in support of market access and reimbursement activities for pharmaceuticals and medical devices. She has extensive experience in value communications, focusing on building impactful value propositions and GVDs to communicate the product value and facilitate market access. Additionally, Persefoni has significant experience in HTA submissions, early drug pipeline assessments, advisory boards and systematic/pragmatic literature reviews. Persefoni has worked in a range of disease areas, including musculoskeletal diseases, gastrointestinal disorders, mental disorders, epilepsy, diabetes, and oncology. Persefoni holds a PhD in Duchenne muscular dystrophy from Newcastle University.

As a health economist, Ewan has been involved in the development of cost-effectiveness and budget impact models as well as survival modelling and data extrapolation, with experience of PRO studies and vignette utility generation. Ewan also has experience conducting systematic and targeted literature reviews alongside quantitative data analysis. He has particular therapeutic knowledge of NASH, immuno-oncologics, Hunter syndrome and Fabry disease.

Andrew has been involved in a broad range of projects at PHMR, including the development, implementation and evaluation of health outcome measures and valuation surveys. Andrew’s knowledge has enabled him to advise clients on strategies for the generation of health-related utility data in rare disease areas to support their HTA submissions. In addition, Andrew has expertise in the methodologies used in the valuation of child health and has presented research in this area at international health economics and health outcomes conferences. His research experience spans a range of indications including oncology and lysosomal storage disorders. Andrew holds an MSc in Health Economics from the University of York.

Ping has been with PHMR since its foundation helping it develop into a successful health economics, pricing and market access consultancy. Coming from a background in clinical pharmacy both in Germany and the UK, she has changed direction in order to lead the contracting and finance team and set up the internal project management structure.

Rachael has been involved with a range of projects at PHMR and has experience conducting multiple stages of systematic reviews and working with meta-analyses. Previous experience in clinical trial management has also allowed her to develop skills in stringent data analysis, leadership and communication with commercial and academic sponsors, as well as clinical trial patients.

Rachel is involved in the development of innovative strategic-based value communications to support in market access, and has a particular interest in the use of creative design and digital media to optimise the usability and impact of value communication materials. Rachel has experience in global value dossier development, treatment landscape analysis, reimbursement pathway mapping, literature reviews, peer-reviewed manuscript development, and stakeholder engagement through advisory boards and interviews. She has knowledge in multiple therapeutic areas including inflammatory bowel disease, anca-associated vasculitis, cystic fibrosis, and renal disease, and a research and publishing background in nutrition and nutraceuticals. Rachel has a PhD in Biological Psychology from Northumbria University.

Philip has significant experience of conducting systematic literature reviews, including data extraction, interpretation, and the communication of results aiming to support HTA submission and for external publication. Philip has contributed to reviews focusing on the clinical effectiveness of interventions as well as the burden of chronic conditions on patients and their caregivers. He has knowledge of several therapeutic areas including oncology, anca-associated vasculitis, and cystic fibrosis.

Alexandra contributes to a broad range of projects at PHMR, including health state valuation, utility measurement, and mapping studies. She has provided clients with advice on strategies for collecting and analysing patient-reported outcomes data in disease areas characterised by fluctuating health-related quality of life. She has also applied her expertise in mapping approaches to support clients’ needs for obtaining utility data required for their HTA submissions. In addition, Alexandra has led work to assess partitioned survival models and Markov models in the context of advanced non-small cell lung cancer. She has an MSc in Health Economics and Decision Modelling from the University of Sheffield.

Craig has extensive experience in conducting systematic and pragmatic literature reviews of clinical and economic evidence alongside quantitative data analyses used to inform HTA submissions and other market access and reimbursement activities. Craig has also been involved in the development of value stories and global value dossiers, ultimately helping our clients build value for their products. He has experience in several disease areas including oncology, epilepsy, hyperkalaemia, and genetic disorders, and has published peer-reviewed research on neuroendocrine tumours. Craig holds a PhD in the broad area of food sustainability from Newcastle University.

Sophie has contributed to a variety of projects including systematic and targeted literature reviews to inform HTA. She has substantial experience in communicating complex information in the form of impactful slide decks and concise global value dossiers. Sophie has worked on multiple project types including treatment landscape analyses, mapping of HTA and reimbursement pathways for rare diseases, and developing recommendations for capturing patient-reported data based on global HTA strategies. Sophie’s interest in market access has led her to coordinate the PHMR monthly market access alerts. She has also worked with clients to publish peer-reviewed research and poster presentations which have been presented at international conferences. She has knowledge of therapeutic areas including oncology, age-related disease, early development, chronic kidney disease and rare diseases. Sophie holds an MRes in Ageing & Health.

Michael has experience in developing communications to demonstrate product value such as evidence-based dossiers. He also has experience in conducting systematic and targeted literature reviews, including data interpretation and synthesis as well as communicating evidence in the form of slide decks, scientific reports, and peer-reviewed manuscripts. Michael has delivered on a range of projects, including reviews of clinical efficacy and burden of illness to support HTA submission and strategic recommendation development. He has knowledge in several disease areas, including oncology, chronic kidney disease, anca-associated vasculitis, diabetes, and cystic fibrosis. Michael has PhD in cellular and molecular biology from Newcastle University.